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Summary
Objective: To design and standardize an in-house reverse line blot hybridization (RLBH) assay for
the accurate identification of 15 clinically relevant species of mycobacteria and for the detection
of drug resistance to rifampin (RIF), isoniazid (INH), and streptomycin (STR) in Mycobacterium
tuberculosis complex (MTB).
Material and methods: Oligonucleotides specific for 15 different species of mycobacteria and
wild type and mutant alleles of selected codons in the rpob, inhA, katG, rpsL, and rrs genes were
designed and immobilized on amembrane. Amultiplex PCR was standardized to amplify all target
genes. The assay was optimized using ATCC and known mutant strains. Three hundred MTB
isolates, 85 non-tuberculous mycobacteria (NTM) isolates, and 48 smear-positive specimens were
analyzed. Results were confirmed by PCR restriction enzyme assay and sequencing.
Results: Upon RLBH analysis, among the NTM, 14% were identified as Mycobacterium fortuitum,
16% were identified asMycobacterium abscessus, 20% showed 99% homology withMycobacterium
intracellulare, and 31% showed 98% homology with Mycobacterium simiae. Of the 300 MTB
isolates analyzed, 75% RIF-resistant isolates had Ser531Leumutation in the rpob gene. Of the INH-
resistant isolates, 89% showed Ser315Thr mutation in the katG gene, whereas 16% showed 15
C!T mutation in the promoter region of the inhA gene. Among STR-resistant isolates, 75% had
A!G mutation in the rpsL gene at codon 43. RLBH results showed 96—99% concordance with
phenotypic culture results.
Conclusion: This is a first attempt at combining speciation with detection of drug resistance to RIF,
INH, and STR in MTB for accurate and rapid management of mycobacterial infections as well as for
compiling genotypic epidemiological data.
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The World Health Organization (WHO) has declared an alarm-
ing increase in the number of tuberculosis (TB) patients in the
Indian subcontinent, with India being singled out as having
the greatest burden.1 Data published from our hospital (P.D.
Hinduja National Hospital and Medical Research Centre), a
tertiary care center in central Mumbai, showed that in 2006,
68% of the patients for whom drug susceptibility testing (DST)
was requested had multidrug-resistant tuberculosis (MDR-
TB).2 Sampling bias cannot be ruled out, as Mumbai is a
hot-spot for MDR-TB.2—4 As a result, there is an urgent need
for rapid and accurate detection of MDR-TB in order to
achieve patient cure and, from a public health perspective,
to prevent transmission.
Although the most important human pathogenic species is
Mycobacterium tuberculosis, there are increasing reports of
infections caused by non-tuberculous mycobacteria (NTM).5,6
Diseases due to NTM, though uncommon, provide a serious
diagnostic and therapeutic challenge. Most of the NTM are
resistant to common anti-TB drugs, and they can be falsely
labeled as MDR-TB if not identified correctly.
In India, the accurate identification of mycobacteria to
the species level is not routine, and the most commonly used
method for TB diagnosis is smear microscopy, which has low
sensitivity and moderate specificity.7 Cultivation of myco-
bacteria is generally performed using conventional Lowen-
stein—Jensen (L.J.) medium, which is time-consuming and
sometimes negative if the disease is paucibacillary or if the
patient is receiving anti-TB therapy. Biochemical tests used
for the identification of mycobacteria are laborious, time-
consuming, and often fail in precise identification.8 DST is
generally performed on L.J. medium by an absolute concen-
tration method. The whole process of detection of drug-
resistant phenotypes of mycobacteria takes at least 4—6
weeks, thus making it hard to meet the demand of initiating
a prompt and effective clinical chemotherapy in patients.
Therefore, most current clinical treatments are often pre-
scribed empirically. In recent years, several new methods
have been reported for reducing the recovery time to 3 weeks
or less.6,9—13 However, in disease endemic developing
nations, these methods require considerable technical
expertise and financial input in a routine laboratory set
up. The development of a rapid, sensitive, and accurate
diagnostic test with prediction of drug susceptibility or resis-
tance would make a substantial impact on TB control activ-
ities.
In the present study, an in-house reverse line blot
hybridization (RLBH) assay was developed and evaluated
for accurate identification of 15 clinically relevant species
of mycobacteria with simultaneous prediction of mutations
causing drug resistance in M. tuberculosis complex (MTB).
In this PCR-based multi-probe assay, 54 specific probes
were used to screen five different genes (rpob (codons
302—534 for speciation and rifampin resistance), katG
(codons 315 and 463), inhA (orf1—inhA promoter region),
rpsL (codons 43 and 88), and rrs (nucleotide positions 491,
513, and 516)), which were amplified by a multiplex PCR.
This was the first attempt at combining simultaneous
species identification of mycobacteria with drug resistance
testing to isoniazid (INH), rifampin (RIF), and streptomycin
(STR) in MTB.Material and methods
Setting
This study was set at a tertiary care center located in central
Mumbai with a referral bias towards non-responding cases.
Subjects
Twenty-two ATCC and CAP-QC strains of mycobacteria and 20
known mutant MTB strains were used to standardize the
assay. In addition, standard ATCC strains of Staphylococcus
aureus, Escherichia coli, Pseudomonas aeruginosa, Salmo-
nella typhi, and Nocardia spp were also tested as negative
controls.
On standardization, the reproducibility of the assay was
checked by analyzing 300 consecutive MTB isolates
reported for susceptibility testing over a period of 7
months (January 2005—July 2005) and 85 consecutive
NTM isolates over a period of 18 months (Jan 2005—June
2006). All these isolates were cultivated using MGIT 960
and L.J., differentiated as MTB or NTM using r-nitroben-
zoic acid (PNBA) on MGIT and r-nitro-a-acetylamino-b-
hydroxypropiophenone (NAP) on BACTEC 460 TB system.
Anti-mycobacterial DST of all MTB isolates was performed
on BACTEC 460 TB system (1% modified proportion
method).
The applicability of this in-house RLBH assay was assessed
by processing 48 AFB smear-positive (1+ and above) clinical
specimens suspected to have aminimumof 10—99 bacilli/100
oil immersion fields.
Definitions
Phenotypic drug resistance was defined as greater than 1%
growth in the presence of 0.1 mg/ml of INH, 2 mg/ml of RIF,
2 mg/ml of STR, and 2.5 mg/ml of ethambutol (EMB).14—16
Multidrug resistance was defined as resistance to at least INH
and RIF. Pan-susceptible isolates were defined as isolates
susceptible to all drugs tested.
DNA extraction
Extraction of genomic DNA from ATCC, CAP-QC, known
mutant strains, and mycobacterial culture isolates was car-
ried out by the CTAB-NACL method described previously.17
DNA extraction from smear-positive clinical specimens was
carried out using the Qiagen DNA extraction kit.
Reverse line blot hybridization (RLBH)
Preparation of membrane for RLBH
Of the 54 specific amino labeled oligonucleotide probes used
for species identification and DST, 10 probes were newly
designed; 44 probes were selected from the previously pub-
lished literature and modified (whenever required) to adjust
length and Tm so that they could be processed under the
same hybridization, washing conditions. All these probes
were covalently linked to a nylon membrane in parallel
lines.18—20 For species identification, oligonucleotide probes
specific for the genus Mycobacterium, as well as 15 clinically
Table 1 Probes labeled on membrane I, for identification of
Mycobacterium tuberculosis complex and mutations causing
resistance to rifampin (RIF), isoniazid (INH), and streptomy-
cin (STR)
No. Probe Gene Description
1 Identification:
MYC
rpob Common for all
mycobacteria
2 MTB rpob M. tuberculosis complex
RIF resistance:
3 RIF wt 1 rpob Codons 509—514
4 RIF wt 2 rpob Codons 514—520
5 RIF wt 3 rpob Codons 521—525
6 RIF wt 4 rpob Codons 524—529
7 RIF wt 5 rpob Codons 530—534
8 RIF mt 1 rpob Codon 533 CTG!CCG
9 RIF mt 2 rpob Codon 531 TCG!TTG
10 RIF mt 3 rpob Codon 531 TCG!TGG
11 RIF mt 4 rpob Codon 526 CAC!TAC
12 RIF mt 5 rpob Codon 526 CAC!GAC
13 RIF mt 6 rpob Codon 526 CAC!TGC
14 RIF mt 7 rpob Codon 526 CAC!CGC
15 RIF mt 8 rpob Codon 526 CAC!CTC
16 RIF mt 8 rpob Codon 526 CAC!AAC
17 RIF mt 9 rpob Codon 522TCG!TGG
18 RIF mt 10 rpob Codon 522TCG!TTG
19 RIF mt 11 rpob Codon 516 deletion
20 RIF mt 12 rpob Codon 516 GAC!TAC
21 RIF mt 13 rpob Codon 516 GAC!GTC
22 RIF mt 14 rpob Codon 516 GAC!GTG
23 RIF mt 15 rpob Codon 516 GAC!GGC
24 RIF mt 16 rpob Codon 513 CAA!CCA
25 RIF mt 17 rpob Codon 511 CTG!CCG
INH resistance:
26 inhA wt inhA MabA—inhA promoter
region
27 inhA mt inhA C!T transition at
codon 15
28 katG 315 wt katG Codon 315 AGC
29 katG 315 mt katG Codon 315 AGC!ACC
30 katG 463 wt katG Codon 463
31 katG 463 mt katG Codon 463
polymorphism C!A
STR resistance:
32 rpsL 43 wt rpsL Codon 43 AAG
33 rpsL 43 mt rpsL Codon 43 AAG!AGG
34 rpsL 88 wt rpsL Codon 88 AAG
35 rpsL 88 mt rpsL Codon AAG!AGG
36 rrs 491 wt rrs Codon 491
37 rrs 491 mt rrs Codon 491-T
38 rrs 513 wt rrs Codon 513 CAG and
516 CCG
39 rrs 513 mt 1 rrs Codon 513 CAG!CCG
40 rrs 513 mt 2 rrs Codon 516 CCG!CTG
wt, wild type; mt, mutant.
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complex, Mycobacterium avium, Mycobacterium intracellu-
lare,Mycobacterium scrofulaceum,Mycobacterium kansasii,
Mycobacterium gastri, Mycobacterium fortuitum complex,
Mycobacterium chelonae, Mycobacterium abscessus, Myco-
bacterium ulcerans,Mycobacterium gordonae, andMycobac-
terium szulgai were synthesized. Similarly for susceptibility
testing the following gene targets were included: rpob
(codons 302—534), katG (codons 315 and 463), inhA (orf1—
inhA promoter region), rpsL (codons 43 and 88), and rrs
(position 491, 513, and 516). Wild type (wt) sequence as
well as the most common mutant (mt) alleles were synthe-
sized to screen the above-mentioned regions. Preliminary
work done on the ahpC gene at our center did not show any
mutations in the ahpC gene among INH-resistant strains
(unpublished data). As mutations causing pyrazinamide
(PZA) resistance are scattered throughout the pncA gene, it
was not convenient to analyze such an extended region of
approximately 600 bp by RLBH assay.21 Hence probes for ana-
lysis ofahpCandpncA geneswere not incorporated in theRLBH
assay. Forty probes were blotted onto a single membrane
(membrane I) for identification of MTB and DST (Table 1).
Sixteenprobes for species identification (Table 2)were blotted
onto the second membrane (membrane II). The uniqueness of
the newly designed and modified probes was analyzed with a
BLAST search (http://www.ncbi.nlm.nih.gov).
In vitro amplification of target genes
Primers were designed with special care to encompass
biotin labeling. The length of the biotin unlabeled primer
was increased in such a way that the minimum difference
between the Tm of the biotin labeled and unlabeled primer
was 8—10 8C. A novel primer pair was designed to amplify
two overlapping regions specific for species identification
and RIF resistance (codons 302—534) of the rpob gene in a
single reaction (Table 3). In the case of rpob, inhA, and rrs
genes, the reverse primer was biotin labeled as the probes
were designed in the forward direction, whereas in the case
of katG and rpsL genes the forward primer was biotin
labeled as the probes were designed in the reverse direc-
tion. These modifications were done as the previous
attempts made by Mokrousov et al. to design probes for
the katG gene and the rpsL gene did not show any hybri-
dization signals due to the secondary structure simulation
for minus strand of katG and rpsL genes.20 Hence the plus
strand was targeted and probes were designed in the
reverse direction.
All the different target gene fragments were amplified
separately and the region of interestwas confirmedby sequen-
cing. Further, tomake this assaymore rapid and cost effective,
a touchdown multiplex PCR was standardized (Figure 1),
wherein a total of 10 important loci on five target genes asso-
ciated with species identification of mycobacteria and resis-
tance testing to INH, RIF, and STR were amplified in a single
reaction using Hotstart Taq polymerase master mix (Qiagen,
Genetix). Positive and negative controls were run at every
step. The amplified products were verified on 2.5% agarose gel
electrophoresis and used to perform the RLBH assay.
Hybridization with amplified products
Heat denatured PCR products were applied on the membrane
in the miniblotter and hybridized at 52 8C (membrane I) and50 8C (membrane II) for 60 min. The membrane was washed
twice with gentle shaking in 250 ml 2  SSPE/0.5% SDS for
10 min at 60 8C (membrane I) and 56 8C (membrane II). The
membrane was subsequently incubated at 42 8C with 1:4000
Table 2 Probes labeled on membrane II, for identification of
clinically relevant species of mycobacteria
No. Probe Description
1 MYC Common for all Mycobacterium species
2 MTB Mycobacterium tuberculosis complex
3 AVI Mycobacterium avium
4 INT Mycobacterium intracellulare
5 SCR Mycobacterium scrofulaceum
6 KAN I Common probe for Mycobacterium
kansasii types I and IV
7 KAN II Common probe for Mycobacterium
kansasii types II, III, and V
8 GAS Mycobacterium gastri
9 FORC Mycobacterium fortuitum complex
10 CHE Mycobacterium chelonae
11 ABS Mycobacterium abscessus
12 ULC Mycobacterium ulcerans
13 GEN/SIM Common probe for Mycobacterium
simiae and Mycobacterium genavense
14 GOR I Common probe for Mycobacterium
gordonae types I, III, and IV
15 GOR II Common probe for Mycobacterium
gordonae type II
16 SZU Mycobacterium szulgai
Figure 1 Amplification of five target genes by touchdown
multiplex PCR (M = molecular weight marker; lanes 1 and
2 = patient sample; PC = positive control; NC = negative con-
trol).
Rapid speciation of 15 clinically relevant mycobacteria 49diluted streptavidin—peroxidase conjugate in 2  SSPE/0.5%
SDS for 60 min, washed twice with 250 ml 2  SSPE/0.5% SDS
at 42 8C for 10 min, rinsed twice with 2  SSPE at RT for
5 min, and subjected to luminescent detection of hybrids
with enhanced chemiluminescence (ECL) detection system
followed by exposure to the ECL Hyperfilm (Amersham Bios-
ciences). The presence of a clearly visible black signal was
considered as a positive hybridization reaction. The results
were easy to interpret (Figures 2 and 3). For reuse, the
membranes were stripped in 1% SDS solution at 80 8C
(2  40 min) and rinsed in 20 mM EDTA, pH 8.0 at RT. The
membranes were re-used up to 7—8 times.Table 3 Primer sequences and PCR conditions to amplify target g
Seq. ID No. Gene Primers
P-1 rpob codons
302—534
Rpo F 50-TCA AGG AGA AGC GCT ACG A
Rpo R 50-biotin-GGG TCT CGA TCG GGC
(Reverse primer biotin labeled)
P-2 inhA TB 92M 50-CCT CGC TGC CCA GAA AGG
TB 93M 50-biotin-CCG GGT TTC CTC CG
(Reverse primer biotin labeled)
P-3 katG KG F biotin-50-AGA GCT CGT ATG GCA C
(Forward primer biotin labeled)
KG R 50-GCG AAT GAC CTT GCG CAG AT
P-4 rpsL STR 52 50-biotin-GTC AAG ACC GCG GCT
(Forward primer biotin labeled)
rpsL R 50-ACG CTT GGG CGC GGG CCC C
P-5 rrs STR 53 50-TCA CCA TCG ACG AAG GTC C
STR 31 50-CTA GAC GCG TCC TGT GCA T
(Reverse primer biotin labeled)Standardization and validation
Standard ATCC strains, CAP-QC strains, and M. tuberculosis
complex strains with known mutations were used to stan-
dardize the probe concentrations and assay conditions for
species identification and drug resistance testing. Over a
period of 2 years, nearly 2500 PCR reactions were performed,
and series of experiments with varying probe concentrations
(1—5000 pmol), different hybridization temperatures (40—
65 8C), washing temperatures (40—60 8C), and different
exposure times (7—45 min) were performed to standardize
the assay conditions. The RLBH assay was successfully stan-
dardized after 85 attempts. Reproducibility of the RLBH assay
was verified by testing 385 clinical isolates and 48 smear-
positive clinical specimens (+1 and above), and results were
compared with phenotypic culture methods as well as with
genotypic methods. All the species identified by RLBH were
confirmed by restriction enzyme (RE) analysis as per work
done by Lee et al.13 Representative strains of all species, wt/enes
Tm 8C Conditions
CC TGG-30 76 95 8C 15 min
ACA T-30 62 (95 8C 1 min 66 8C 1 min 72 8C 1 min)  2c
GAT CC-30 74 (95 8C 1 min 65 8C 1 min 72 8C 1 min)  2
G T-30 54
CG GA-30 62 (95 8C 1 min 64 8C 1 min 72 8C 1 min)  2
C-30 66
CTG A-30 62 (95 8C 1 min 63 8C 1 min 72 8C 1 min)  2
-30 70
G GG-30 72 (95 8C 1 min 62 8C 1 min 72 8C 1 min)
 30/35
G-30 64 72 8C 5 min Hold at 15 8C
Figure 2 Membrane I for identification of Mycobacterium tuberculosis complex and drug resistance testing. On membrane I, all
amino labeled probes are blotted vertically and then biotin labeled heat denatured PCR product is applied horizontally. Lane 1
corresponds to probe common for all mycobacteria. Lane 2 has probe for M. tuberculosis complex. Lanes 3—7 are five wt probes for
detection of rifampin (RIF)-susceptible strains. Lanes 8—25 are 18 mt probes for detection of rifampin resistance. Lanes 26 and 27 are
inhAwt and mt probes, respectively, for isoniazid (INH) resistance. Lanes 28 and 29, 30 and 31 represent wt and mt probes for codons
315 and 463 in the katG gene, respectively. Lanes 32—35 correspond to codons 43 and 88 of rpsL wt and mt probes, respectively, for
streptomycin (STR) resistance. Similarly lanes 36—40 correspond to wt and mt probes for nucleotide positions 491, 513, and 516 in the
rrs gene. Horizontal lanes 1—31 represent heat-denatured PCR products, i.e., patient samples or isolates. To illustrate one example,
patient 10 has mycobacterial infection due to M. tuberculosis complex and hybridization signal with all RIF wt probes and none of the
mt probes; therefore it is RIF-susceptible. Similarly it shows hybridization with inhA, katG, rpsL, and rrs — all wt type probes — hence it
is sensitive to INH and STR. In the case of patient 2, there is mycobacterial infection due toM. tuberculosis complex, however the strain
is resistant to RIF as there is no hybridization signal with wt probe 4, but hybridization with probe 19, which is a 516 TAC mutation.
Similarly in the same patient there is hybridization signal with inhAwt and katG mt indicating INH resistance due to mutation in katG
gene codon 315. In the case of STR, the same patient’s sample showed hybridization signal with rpsL codon 43 and 88 wt type probes
and rrs gene codons 491 wt and 516 mt probes. So the strain is resistant to STR due to mutation at codon 516 of the rrs gene. Hence the
patient’s strain is M. tuberculosis complex resistant to RIF, INH, and STR.
50 S. Shenai et al.mt alleles, and all the mutants not binding to wt and mt
probes were further confirmed by sequencing.
Fingerprinting
Fingerprinting was carried out by spoligotyping to check the
clonality and mutation patterns in different clusters.18
Results
The different species identified by RLBH assay are described
in Table 4. All 300 MTB isolates were correctly identified by
RLBH. Among 85 NTM, 26 were rapidly growing mycobacteria
(RGM), identified as M. fortuitum (46%) and M. abscessus
(54%). Of the 59 slowly growing NTM, 17 (29%) showed 99%homology with M. intracellulare and 26 (44%) showed 98%
homology with M. simiae. Other NTM identified included M.
kansasii (5%), M. gordonae (5%), and M. szulgai (1.7%), and
one isolate (1.7%) showed 95% homology with M. avium.
Mixed infections (MTB + NTM) were noticed in three cases.
Interestingly, all patient isolates identified as M. intracellu-
lare by RLBH showed the standard RE pattern of 175—100—80
with MspI digest; however with HaeIII enzyme they showed a
slightly different pattern of 180—100 instead of 180—90.
Further sequencing of all these strains showed insertion of
12 nucleotides in the rpob gene. There were five patient
strains identified as NTM by phenotypic NAPand PNBA results,
however they were confirmed as MTB by RLBH.
As described in Table 5, of the 300 MTB isolates, 179 were
isolated from pulmonary specimens and 121 from extrapul-
Figure 3 Membrane II for species identification of mycobac-
teria. All the different amino labeled probes are blotted verti-
cally. Then heat-denatured biotin labeled PCR products are
applied horizontally. If the infection is due to mycobacteria,
hybridization will be observed with probe 1, which is common for
all mycobacteria. Further, depending upon the species, hybridi-
zation will be observed with the corresponding probes repre-
senting that species, e.g., patient 1 has mycobacterial infection
due toM. tuberculosis complex, whereas in the case of patient 3
there is an infection due toM. abscessus as it shows hybridization
with probe 11 corresponding to M. abscessus. In the case of
mixed infection one can get the hybridization signal with two
different species. Similarly if the infection is due to some other
mycobacterial species that is not clinically relevant or not
targeted, there will be a hybridization signal with probe 1 and
there will not be any hybridization signal with any of the other
probes.
Rapid speciation of 15 clinically relevant mycobacteria 51monary specimens. Of the total, 63% were resistant to one or
more anti-TB drugs phenotypically. Resistance to INH was
found to be 60%, whereas resistance to RIF was 53% and STR
was 46%. Among pulmonary isolates, the MDR-TB rate was
found to be 70%, whereas in the case of extrapulmonary
isolates the MDR-TB rate was only 26%.
Mutations in the rpob gene were detected in 169 cases by
RLBH assay (Table 6), of which 158 MTB isolates were resis-
tant to RIF phenotypically. Of the 11 isolates showing muta-
tions by RLBH, 10 were found to be resistant to INH
phenotypically. We observed 22 different types of mutations.
The codons most frequently involved in mutations were
codon 531 (76%), codon 526 (7%), and codon 516 (9%). The
most common mutation, Ser531Leu (TCG!TTG), was found
in 126 of the 169 RIF-resistant isolates (75%). Double muta-
tions were observed in five strains and deletion of codon 516
was noticed in two strains. No mutations were detected in
two RIF-resistant strains. Compared to phenotypic DST, the
concordance of the RLBH assay for the detection of RIF
resistance was 96%.
As summarized in Table 7, of the 179 INH-resistant cases,
82% of resistant strains showed the mutation G!C at codon
315 in the katG gene, 9% showed the 15 C!T mutation inthe in inhA gene promoter region, while 7% isolates showed
both the inhA 15 + katG 315 mutations together. Overall
89% of the INH-resistant isolates had a Ser315Thr mutation at
codon 315. Seventy nine percent of our strains showed C—A
polymorphism at codon 463 in the katG gene. The katG
deletion was not detected in any of the INH-resistant iso-
lates. Overall 99% concordance was observed with phenoty-
pic DST for INH.
Among STR-resistant isolates (Table 8), themost prevalent
mutation was the single substitution Lys43Arg in the rpsL
gene found in 75% of the isolates analyzed. The other muta-
tion in the rpsL genewas substitution Lys88Arg found in 12% of
the STR-resistant isolates. Five percent had the Gln513Pro
mutation at nucleotide position 513 and 6% had Pro516Leu
mutation at position 516 in the rrs gene. Not a single STR-
resistant isolate showed mutation at position 491 in the rrs
gene. Two percent of our clinical isolates did not show any
mutations in the targeted region. It is also worth noting that
none of the tested strains had rpsL and rrs gene mutations
simultaneously. The RLBH results for STR resistance showed
98% concordance with the phenotypic DST.
Finally, the applicability of this assay was analyzed in 48
smear-positive (1+ and above, i.e., 10—99 bacilli/100 oil
immersion fields) clinical specimens and the results obtained
are summarized in Table 9. All were identified as MTB by
RLBH. Of the 48, 14 were identified as wt to all the target
genes and hence susceptible to RIF, INH, and STR. The
remaining 34 were resistant to INH (Table 9). Twenty-four
had the Ser315Thr mutation in katG, three had the 15 C—T
mutation at the inhA promoter region, whereas seven speci-
mens showed the presence of both these mutations, i.e.,
Ser315Thr in katG gene and —15 C—T in inhA gene together.
Thirty-two showed mutations at codons 531, 516, and 513 in
the rpob gene, hence they were resistant to RIF. Twenty-six
RIF-resistant specimens had the Ser531Leu mutation in the
rpob gene. Twenty-three specimens were identified as STR-
resistant by RLBH assay. Twenty showed mutation Lys43Arg in
the rpsL gene, two had the Lys88Arg mutation in the rpsL
gene, whereas one specimen showed Pro516Leu change in
the rrs gene. When applied directly to the smear-positive
clinical specimen results of both species, identification and
resistance testing to INH, RIF, and STR were available within 4
working days (Table 10).
Discussion
Rapid and accurate identification of mycobacteria with
prompt anti-mycobacterial susceptibility testing is the cor-
nerstone for the treatment of infected patients and for
preventing pathogen spread to others. We have described
an in-house RLBH method for simultaneous species identifi-
cation and detection of mutations associated with multiple
drug resistance in MTB.
The 360-bp region of the rpob gene targeted for speciation
(codons 302—340) is located near the rpob mutation sites for
RIF resistance (codons 509—534), so both these regions can
be amplified together for both speciation and RIF resistance.
A novel primer pair was designed to amplify both these
overlapping regions (total 564 bp) simultaneously as a single
reaction. We further standardized a touchdown multiplex
PCR wherein all five target genes viz. rpob, katG, inhA, rpsL,
and rrs were amplified together.
Table 4 Analysis of mycobacterial isolates (N = 385) for species identification by RLBH and comparison with culture, PCR-RE, and
sequencing
No. of
isolates
AFB
culture
RLBH PCR-RE analysis Sequencing
MspI HaeIII Species
6 RGM M. fortuitum 175—100—70 120—90—80 M. fortuitum
type I
M. fortuitum
type I (4 strains)
6 RGM M. fortuitum 105—95—80—70 120—90—80 M. fortuitum
type II
M. fortuitum
type II (2 strains)
14 RGM M. abscessus 105—95—80—45 130—100—90 M. abscessus M. abscessus
(4 strains)
17 NTM M. intracellulare 175—100—80 180—100 M. intracellulare M. intracellulare
(4 strains)
26 NTM GEN/SIM 175—100—70—45—35 180—110 M. simiae M. simiae
(6 strains)
3 NTM M. kansasii 175—60—40 205—90 M. kansasii
type I
M. kansasii
type I (1 strain)
3 NTM M. gordonae 145—95—40—30 210—95—90 M. gordonae
type I
M. gordonae
type I (1 strain)
1 NTM M. avium 120—90—40 210—100 Could not be
interpreted
95% homology with
M. avium
1 NTM M. szulgai 175—80—40 100—115 M. szulgai M. szulgai (1 strain)
1 NTM MTB +
M. gordonae
145—95—80—60—40—30 250—95—90 Indeterminate
(mixed RE pattern)
MTB + M. gordonae
type I (1 strain)
1 NTM MTB +
M. simiae
175—100—80—70—60—40 250—180—100 Indeterminate
(mixed RE pattern)
MTB complex
+ M. simiae
(1 strain)
1 NTM MTB +
M. fortuitum
175—100—95—80—60—40 250—120—100—80 Indeterminate
(mixed RE pattern)
MTB complex
+ M. fortuitum
(1 strain)
5 NTM MTB 175—80—60—40 250—100 MTB complex MTB complex
(3 strains)
300 MTB
complex
MTB complex
(300 strains)
175—80—60—40 250—100 MTB complex
(25 strains)
MTB complex
(25 strains)
RLBH, reverse line blot hybridization; PCR-RE, PCR-restriction enzyme assay; AFB, acid-fast bacillus; RGM, rapidly growing non-tuberculous
mycobacteria; NTM, non-tuberculous mycobacteria; MTB, Mycobacterium tuberculosis complex; GEN/SIM, Mycobacterium simiae and
Mycobacterium genavense.
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good hybridization results. Probes common for the genus
Mycobacterium and MTB were incorporated on membrane I
along with different wt and mt probes for resistance
testing. Probes for different genes were immobilized on
the membrane side by side, and the hybridization was
performed simultaneously with five amplified PCR frag-
ments. This did not influence the strength of the signalsTable 5 Analysis of Mycobacterium tuberculosis complex isolates
Pulmonary specim
179 (60%)
Pan-susceptible (sensitive to all drugs) 34 (19%)
Resistant to one/more drugs 145 (81%)
Resistant to INH 140 (78%)
Resistant to RIF 127 (71%)
Resistant to STR 113 (63%)
Resistant to EMB 91 (51%)
MDR (resistant to INH and RIF) 125 (70%)
INH, isoniazid; RIF, rifampin; STR, streptomycin; EMB, ethambutol; MDRand did not show any cross-reaction with other PCR pro-
ducts. The signal strength decreased slightly on reuse of
membrane up to 7—8 times but this did not affect evalua-
tion. As in more than 95% of the cases infection was due to
MTB, maximum information was obtained using this single
membrane. PCR products not showing any hybridization
signal with an MTB probe were further processed on mem-
brane II for speciation.(N = 300) and drug susceptibility by phenotypic method
ens Extrapulmonary specimens
121 (40%)
Total
78 (64%) 112 (37%)
43 (36%) 188 (63%)
39 (32%) 179 (60%)
31 (26%) 158 (53%)
25 (21%) 138 (46%)
28 (23%) 119 (40%)
31 (26%) 156 (52%)
, multidrug-resistant.
Table 6 Mutations observed in the rpob gene by RLBH assay (N = 169)
Mutation No. % In-house RLBH assay Change confirmed
by sequencing
Serine!leucine (S531L) 126 74.6 531 TCG!TTG 531 TCG!TTG
Serine!leucine (S531L) 2 1.2 531 TCG!TGG 531 TCG!TGG
Histidine!aspartate (H526D) 2 1.2 526 CAC!GAC 526 CAC!GAC
Histidine!tyrosine (H526Y) 3 1.8 526 CAC!TAC 526 CAC!TAC
Histidine!cysteine (H526C) 4 2.4 526 CAC!TGC 526 CAC!TGC
Histidine! (H526R) 1 0.6 526 CAC!CTC 526 CAC!CTC
Histidine! (H526) 2 1.2 526 CAC!CGC 526 CAC!CGC
Aspartate!tyrosine (D516Y) 5 3 516 GAC!TAC 516 GAC!TAC
Serine S522Q 1 0.6 No hybridization signal
with wild type probe 3 and
none of the mutant probes
522 TCG!CAG
Aspartate!Glu (D516V) 7 4.1 516 GAC!GTC 516 GAC!GTC
Aspartate!glycine (D516G) 2 1.2 516 GAC!GGC 516GAC!GGC
Deletion of codon 516 2 1.2 516 DGAC 516 DGAC
Gln!leucine (Q513L) 1 0.6 No hybridization signal
with wild type probe 1 and
none of the mutant probes
513 CAA!CTA
Gln!lysine (Q513K) 1 0.6 No hybridization signal
with wild type probe 1 and
none of the mutant probes
513 CAA!AAA
Gln!lysine (Q513K) 1 0.6 513 CAA!CCA 513 CAA!CCA
Leucine!proline (L511P) 1 0.6 511 CTG!CCG 511 CTG!CCG
Deletion of codons 509—511 1 0.6 No hybridization signal
with wild type probe 1
and none of the mutant probes
D AGC, CAG, CTG
Methionine!leucine (M515L) 1 0.6 No hybridization signal
with wild type probes 2 and 4
515 ATG!CTG
Histidine!cysteine (H526C) Mutant 526 CAC!TGC 526 CAC!TGC
Asparagine!aspartate (H518D) 1 0.6 No hybridization signal
with wild type probes 2 and 4
518 AAC!GAC
Histidine!asparagine (H526N) Mutant 526 CAC!AAC 526 CAC!AAC
M515V 1 0.6 No hybridization signal
with wild type probes 2 and 4
515 ATG!GTG
L511P Mutant 511 CTG!CCG 511 CTG!CCG
M511I 1 0.6 No hybridization signal
with wild type probes 1 and 4
and hybridization with mutant probe
511 ATG!ATT
Histidine!asparagine (H526N) 526 CAC!AAC 526 CAC!AAC
Aspartate!tyrosine (D516Y) 1 0.6 516 GAC!TAC 516 GAC!TAC
Asparagine!aspartate (H518D) No hybridization signal
with wild type probes 1 and 3
518 AAC!GAC
Undetected 2 1.2
RLBH, reverse line blot hybridization.
Rapid speciation of 15 clinically relevant mycobacteria 53As demonstrated in Table 5, in the case of 300 MTB
isolates, 100% concordance was observed between RLBH
results and phenotypic PNBA and NAP results. However of
the 85 NTM detected by phenotypic methods, five were
identified as MTB by RLBH. Further analysis of these five
isolates by RE and sequencing confirmed that these isolates
were falsely identified as NTM by phenotypic methods.
Amongst the RGM, M. fortuitum complex and M. abscessus
were predominant, whereas among the slowly growing NTM,
M. intracellulare and M. simiae were predominant. Mixed
infections were noticed in three cases by RLBH. The advan-
tage is that both species can be identified to the species level
using this assay, which is sometimes difficult using phenotypicculture methods due to overgrowth of NTM over the slower
growing MTB. All patient isolates identified as M. intracellu-
lare showed insertion of 12 nucleotides in the rpob gene. This
has not been reported before.
Since NTM are ubiquitous in nature, the isolation of these
organisms from specimens should meet certain criteria to
confirm their etiological significance, such as: (a) repeated
isolation of the same organism from a patient, (b) associated
positive clinical and radiological evidence and (c) histopatho-
logical confirmation, (d) presence of any predisposing fac-
tors/underlying diseases, and (e) the immune status of the
patient — this aids in assessing the pathogenesis of NTM when
isolated.22,23 In the present study, 49% of patients met the
Table 7 Mutations observed in isoniazid-resistant strains by
RLBH assay (N = 179)
Region Number
(%)
Amino acid change
by sequencing
inhA gene promoter
region
16 (9%) 15 C!T
katG gene 147 (82%) S315T G!C
inhA promoter
region + katG
13 (7%) 15 C!T and S315T
Undetected 3 (2%)
RLBH, reverse line blot hybridization.
Table 8 Mutations observed in streptomycin-resistant strains
by RLBH assay (N = 138)
Region Number (%) Amino acid change
by sequencing
rpsL 43 mt 103 (75%) AAGLys!AGGArg
rpsL 88 mt 17 (12%) AAGLys!AGGArg
rrs 513 mt 7 (5%) CAGGln!CCGPro
rrs 516 C—T 8 (6%) CCGPro!CTGLeu
Undetected 3 (2%)
RLBH, reverse line blot hybridization. mt (mutant) denotes resistant
strains.
54 S. Shenai et al.American Thoracic Society (ATS) criteria andwere considered
as true infections. The prevalence of AIDS in our patient
population was less than 2%, indicating that the infections
due to NTM are increasing even in non-HIV patients.
Although there have been reports from India, the exact
disease burden of NTM infections in India remains unclear.
These infections are under-diagnosed in many laboratories
due to lack of facilities and expertise. Our findings clearly
emphasize the need for speciating all mycobacterial isolates.
As most NTM are not susceptible to conventional anti-TB
treatment, it is desirable to identify these isolates to the
species level, particularly from AIDS and drug-resistant cases
to avoid them being misinterpreted as MDR-TB.Table 10 Comparison of in-house RLBH assay with phenotypic m
Identification and recovery Susceptib
line drugs
Rate Time Efficiency
L.J. Media 30—50% 2—8 weeks 80—99%
BACTEC 460 50—70% 2—3 weeks 92—100%
MGIT 960 50—70% 1—2 weeks 98.6—100
RLBH assay 95—98% 4 days 98%—100%
RLBH, reverse line blot hybridization.
Table 9 Analysis of smear-positive clinical specimens by RLBH (N =
Drug Gene Suscep
Rifampin (RIF) rpob 2
Isoniazid (INH) 0
inhA
katG
inhA + katG
Streptomycin (STR) 11
rpsL codon 43
rpsL codon 88
rrs codon 516
RLBH, reverse line blot hybridization.
a M. tuberculosis complex = 48; wild types to all target genes (pan-sus
one or more genes) = 34.For resistance testing, the presence of mutations was
demonstrated either by hybridization to the corresponding
probe representing the mt probe or by loss of hybridization to
the respective wt genotype only. In nine cases, we observed
loss of hybridization to the respective wt genotype only. This
hybridization pattern could not tell the accurate mutation
genotype, but could still detect the mutations associated
with RIF resistance. Further confirmation of these nine iso-
lates by sequencing showed deletion of three codons — 509,
510, and 511 — in one isolate. Non-targeted mutations at
codons 522, 518, 515, and 513 were observed in the remain-
ing eight isolates with double mutations in five cases. Inter-
estingly the mutations AAC at codon 526, GAC at codon 518,ethods
ility testing for first- Total time for identification and
susceptibility testing
Time
2—4 weeks 4—12 weeks
8—10 days 3—5weeks
% 6—10 days 2—4 weeks
4 days 4 days
48):a detailed screening of all 34 isoniazid-resistant specimens
tible Resistant mutants
32
Mutations identified: S531L (26), S531W (1),
D516V (2), D516Y (2), Q513K (1)
34
Mutations identified:
15 C—T (3)
S315T (24)
15 C—T + S315T (7)
23
Mutations identified:
Lys43Arg (20)
Lys88Arg (2)
Pro516Leu (1)
ceptible) = 14; resistant to one or more drugs (mutation detected in
Figure 4 Diagrammatic representation of a false susceptible result obtained by reverse line blot hybridization (RLBH).
Rapid speciation of 15 clinically relevant mycobacteria 55and ATT or CTG at codon 515 did not occur alone and were
present in isolates with more than one mutation. As summar-
ized in the Table 6, screening of the rpob gene for RIF-
resistant strains revealed that 98.8% of the strains had
mutations in the 80 bp core region. Various investigators
have reported a rate of 20—70% for mutation at codon
Ser531Leu (TCG to TTG) in the rpob region for RIF-resistant
strains, followed by 0—30% at codon 526 (CAC to GAC).24,25
Indian studies carried out so far have reported rates of 39—
53% for mutation at codon 531,26—28 whereas we found this
mutation at amuch higher rate (75%) in RIF-resistant isolates.
Mutations were not detected in two phenotypically RIF-
resistant cases. Further, sequencing of these isolates showed
an insertion of codon 514 in the rpob gene in one of the
isolates, whereas no mutation was observed in the RIF resis-
tance determining region (RRDR) of the rpob gene in the
remaining isolate. The occurrence of 514 TTC insertion in the
rpob gene is rare and has been reported previously.29 Of the
five wt probes designed for screening the RRDR of the rpob
gene, RIF1W covers the codons 509—514 whereas RIF2W
covers the region of codons 514—520 (Figure 4). As codon
514 is located close to the 30 end of the RIF1W probe (codons
509—514), and it is the starting point of the 50 end of the
RIF2W probe (codons 514—520), both the probes showed good
hybridization signals. Therefore it was falsely identified as a
RIF-susceptible strain instead of resistant. This problem can
be overcome by increasing the length of the RIF1W probe.
Conversely, 11 phenotypically RIF-susceptible isolates
were revealed to harbor a mutation in the rpob gene. Inter-
estingly 10/11 were found to be resistant to INH phenotypi-
cally. In seven of these 11 cases, mutations were found to be
present at codons 522, 518, 516, 515, and 511, which have
been reported to cause low level resistance, whereas in the
remaining four cases the mutations were at codons 531 and
526, which have been reported to cause high level resistance.
All these isolates were rechecked by both the methods and
finally confirmed by sequencing. Phenotypic DST was per-
formed using BACTEC 460 TB system, which cannot deter-
mine the actual proportions of resistant bacteria in
culture.30,31 In addition, there is evidence that the BACTEC
method may not be a reliable tool for determining resistance
in cultures containing less than 10% drug-resistant bac-
teria,30,31 hence all these cases were identified as suscep-
tible phenotypically.
INH is a key component of the anti-tuberculosis, short
course chemotherapy. Various studies have shown that the
mutation Ser315Thr in the katG gene is most abundant and
present in the 33—97% of INH-resistant strains reported
worldwide.22,32—35 The prevalence of this mutation is found
to be highest in isolates recovered from patients of South
Asian origin and lowest in isolates from patients of Middle
Eastern origin. This mutation has specifically been reportedto be predominant (>90%) amongst the MDR isolates from
Russia and Latvia.35,36 In our study, overall 89% of the INH-
resistant isolates had this mutation. Variation in katG 463 has
no relation to INH resistance and was included on the mem-
brane as a marker frequently used in evolutionary studies. In
particular, katG 463-Leu is indicative of group I (presumably
the most ancient).37 In the present study, this allele was
found in the majority (79%) of the isolates. The C!T muta-
tion at the 50 end of a presumed ribosome-binding site of inhA
promoter was found in overall 16% of our patient population.
In the present study, 87% of STR-resistant clinical isolates
showed mutations in the rpsL gene at codons 43 and 88
(Table 8). Eleven percent showed mutations in the rrs gene
at positions 513 and 516. Mutations in rpsL and rrs genes were
shown to confer STR resistance in up to 80% of STR-resistant
MTB isolates.38,39 In comparison, our results showed higher
mutations (87%) in the rpsL gene and 11% in the rrs gene.
Three (2%) of the STR-resistant culture isolates did not show
any mutations in the rpsL or rrs genes. These isolates prob-
ably acquired resistance by other means. None of the STR-
susceptible isolates examined had alterations in the rpsL or
rrs genes.
Application of the RLBH assay on culture isolates is still
time-consuming, as mycobacterial growth takes 2—6 weeks.
To further reduce the time, the applicability of this assay was
analyzed in 48 smear-positive (1+ and above, i.e., 10—99
bacilli/100 oil immersion fields) clinical specimens and the
results obtained are summarized in Table 9. Of these 48
smear-positive specimens, four were from patients who
had been receiving anti-TB treatment for various periods
of time, and culture was negative in all these patients even
after 6 weeks. In contrast, RLBH results were available within
4 days of specimen collection (including the time required for
DNA extraction, amplification, RLBH, and results analysis)
and correlated well with the clinical picture of all these
patients. This highlights the importance of RLBH analysis in
cases where the culture is negative and DST cannot be
performed. The technique was found to be rapid and repro-
ducible in smear-positive clinical specimens with a total turn-
around time of only 4 working days for both identification and
susceptibility testing.
Comparison of the RLBH assay with commercially avail-
able kits for rapid detection of MDR-TB is shown in Table 11.
Commercial assays have separate kits for species identifica-
tion of mycobacteria and separate kits for detection of drug
resistance. Tests like the InnoLiPA for RIF resistance can
detect MTB targeting 23SrRNA—16SRNA and cover only the
four most frequently observed mutations viz. D516V, H526Y,
H526L, and S531L in the rpob gene. Of the two commercially
available line probe assays, the Hain test is used to detect
katG gene mutations, however it is not available in India.
They do not target any mutation for STR resistance. In the
Table 11 Comparison of in-house RLBH assay with commercially available line probe assays
In-house RLBH assay Genotype MTBDR
(Hain Life Sciences)
InnoLiPA Rif.TB (Innogenetics)
Species identification M. tuberculosis complex
+ 14 clinically relevant
species of NTM
M. tuberculosis complex M. tuberculosis complex
Gene targeted for
species identification
rpob 23S-rRNA/16-RNA 23S-rRNA
DNA amplification Multiplex PCR for five
target genes
Multiplex PCR for two
target genes
PCR
Direct application to
clinical specimens
Yes Yes Yes (new version)
Mutations targeted
rpob 17 mutations (25 probes) 4 mutations (9 probes) 4 mutations (9 probes)
katG 4 mutations 4 mutations Not included
inhA 1 mutation (2 probes) 1 mutation (2 probes) Not included
rpsL 2 mutations (4 probes) Not included Not included
rrs 3 mutations (5 probes) Not included Not included
Assay description Blot assay Strip assay Strip assay
Cost per test (Rs, Indian rupee) 1500/- Not available in India 5000/-
RLBH, reverse line blot hybridization; NTM, non-tuberculous mycobacteria. RLBH has been approved as a new diagnostic test in our hospital.
56 S. Shenai et al.present study 22 different types of mutations were observed
in RIF-resistant isolates. Of the total mutations observed in
RIF-resistant cases, only 82% can be detected through the
resistant probes targeted by commercial assays. In our RLBH
assay probes for detection of mutations on rpsL, rrs are also
included to detect resistance to STR. The advantage of the
in-house RLBH assay is that more probes can be designed and
incorporated as per the regional variations depending on the
epidemiological data.
Commercial assays are strip-based assays hence use one
strip per patient. In contrast this in-house RLBH assay is a blot
assay. At times, 40 different patient samples can be screened
using a single membrane and common reagents like washing
solutions, hybridization solutions, and detection reagents. It
is easy to handle, and as for the spoligotyping membrane,
once prepared the membrane can be used at least 7—8 times.
In resource-limited settings, approximately 320 patients can
be screened using a single membrane. Analysis of multiple
samples and reuse of themembranes further reduces the cost
of the assay without affecting the quality of results. The cost
of the current commercial LiPA kit is $45 per sample tested.
When additional costs for import and transport are taken into
account, the actual cost per sample is as high as $116, i.e.,
approximately 5000 Indian rupees (Rs).40 This high price
precludes the wide application of this assay in the geographic
areas where it is most urgently needed; our in-house assay
costs approximately Rs 1500 per sample for speciation with
detection of MDR and SM resistance. Hence it is suitable for
application in the routine clinical laboratory, especially in
developing countries.
Results of this study indicate a high predominance of rpob
531, katG 315, and rpsL 43 mutations in our MDR-TB isolates.
Further analysis of all these MDR isolates by spoligotyping
showed the prevalence of Beijing genotype; 54% of MDR
isolates belong to Beijing genotype showing an increase from
the previously reported 35%.41 Among this Beijing group, 84%
of RIF-resistant strains showed Ser531Leu mutation in therpob gene, 96% Ser315Thr at codon 315 in the katG gene, and
83% STR-resistant strains showed Lys43Arg at codon 43 in the
rpsL gene. As reported previously,35,41—43 we also observed
the predominance of katG codon 315 mutations in Beijing
genotype. This high resistance should be interpreted with
caution as it is from a tertiary care center with a referral bias
towards non-responding cases and so is not representative of
the prevalence of resistance in the nation.
To summarize, we have successfully standardized an in-
house RLBH assay, the first of its kind for species identifica-
tion with simultaneous drug resistance testing to INH, RIF,
and STR in MTB. Results of this study indicate a high pre-
dominance of rpob 531, katG 315, and rpsL 43 mutations
among Beijing genotype and MDR-TB isolates. Therefore, the
in-house RLBH assay can be a practical tool for rapid detec-
tion of multiple point mutations in the routine diagnostic
workup. The method is rapid, requires the same equipment
as that used for spoligotyping, and allows for the analysis of
up to 40 samples simultaneously. Multiple point mutations
can be screened in this single experiment and results are
available within 4 working days when applied directly to the
smear-positive clinical specimens. Besides being cost effec-
tive, this assay enables earlier treatment and prompt imple-
mentation of infection control procedures to reduce the
morbidity and mortality and the spread of MDR-TB. The
present RLBH is an adequate tool for the direct analysis of
MDR-TB in clinical specimens and fulfills many of the attri-
butes of an ideal TB diagnostic test as proposed by the WHO
for developing countries.
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